Boothbay Fund Management’s Stoke Therapeutics STOK Stock Holding History

Boothbay Fund Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.65M	Buy	80,968 +33,661	+71%	+$1.08M	0.03%	590
2026 Q1	$1.54M	Buy	+47,307	New	+$1.55M	0.02%	740
2023 Q3	–	Sell	-14,180	Closed	-$93.2K	–	2060
2023 Q2	$151K	Buy	+14,180	New	+$151K	﹤0.01%	1543
2022 Q3	–	Sell	-205,463	Closed	-$3.27M	–	2586
2022 Q2	$2.71M	Hold	205,463	–	–	0.07%	419
2022 Q1	$4.33M	Buy	+205,463	New	+$4.11M	0.1%	252

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boothbay Fund Management's STOK Position: Q2 2026 in Review

Boothbay Fund Management increased its Stoke Therapeutics (STOK) stake by 71% in Q2 2026, buying an estimated $1.08M and bringing the position to 80,968 shares worth $2.65M. The position accounts for 0.03% of the portfolio, ranked #590.

Boothbay Fund Management first reported a position in STOK in Q1 2022 and has held it in 5 quarters since. The position peaked at $4.33M in Q1 2022. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

Boothbay Fund Management held 80,968 shares of Stoke Therapeutics worth $2.65M as of Q2 2026.
Boothbay Fund Management bought 33,661 Stoke Therapeutics shares in Q2 2026, an estimated $1.08M.
Stoke Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #590 holding.
Boothbay Fund Management first reported a position in Stoke Therapeutics in Q1 2022 and has held it in 5 quarters since.
Boothbay Fund Management's Stoke Therapeutics position peaked at $4.33M in Q1 2022.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.